Dr. Wang Yinxiang is currently Chairman and Co-CEO of Jacobio.

Dr. Wang Yinxiang has more than 30 years of experience oncology research. He once led the research and marketing of icotinib hydrochloride (Conmana^®, the first targeted anti-tumor drug in China). Before he established Jacobio, he served as CEO and CSO of Betta Pharmaceuticals (300558.SZ).

Dr. Wang Yinxiang earned his Ph.D. from the University of Arkansas for Medical Sciences, USA. After that, he was engaged in postdoctoral research in the Department of Molecular Biophysics and Biochemistry, Yale University. Now, he is the vice chairman of the Anti-tumor Drug Professional Committee of the Chinese Pharmaceutical Association, and vice chairman of the New Drug R&D Committee of the China Pharmaceutical Innovation and Research Development Association (PHIRDA).

Dr. Andrea Wang-Gillam is the Co-CEO, CMO and Global Head of R&D at Jacobio. She is in charge of international business development, global clinical operations and partnerships.

An expert in gastrointestinal oncology, Dr. Wang-Gillam has more than twenty years of research experience in clinical and translational oncology. Born into a family of doctors, she is passionate about prospective research into cancer. Prior to joining Jacobio, she was an oncologist, Director of Gastrointestinal Oncology, and Director of the Early Clinical Trial Center at Washington University School of Medicine in St. Louis, U.S., and served as Principal Investigator (PI) in more than 60 clinical trials. She led the NAPOLI-1 Phase III clinical study of irinotecan liposome injection (Onivyde®), which was later approved for commercialisation in the U.S., Europe, and across Asia.

Dr. Wang-Gillam obtained her M.D. and Ph.D. in molecular biology from the University of Arkansas for Medical Sciences, U.S. She has published more than 100 peer-reviewed papers and been the lead author in multiple papers published in international top-tier journals such as The Lancet, The Lancet Oncology, and the Journal of Clinical Oncology.

Wang Yanping is currently the Executive Vice President of Preclinical R&D at Jacobio.

Wang Yanping is responsible for preclinical R&D. Under her leadership, her team has completed preclinical studies of multiple innovative drugs that have been granted investigational new drug (IND) approvals in both China and the U.S.

Having worked for nearly 20 years in the research and development of new drugs, Wang Yanping has extensive experience in the evaluation of novel drugs, preclinical development and investigational new drug (IND) submissions. Prior to joining Jacobio, she was the Director of the Pharmacology Department of Betta Pharmaceuticals’s R&D Center.

Wang Yanping holds a bachelor’s degree in biology and a master’s degree in physiology from Nanjing University. She was once granted the title of The 23rd Beijing Outstanding Young Engineer.

Ding Yuli, Executive Vice President of Clinical Development at Jacobio, built clinical study teams in China and the United States, participates in strategy formulation for clinical development and is responsible for the implementation, operation, and management of clinical studies.

Ding Yuli has more than 20 years of clinical development experience. Prior to working for Jacobio, she worked for Janssen Pharmaceuticals, GlaxoSmithKline and Sihuan Pharmaceuticals. She has led teams that have completed registrational studies related to nearly 20 projects in both international multi-center and domestic studies. During her tenure at Janssen, she won the President's Award and the Global Leadership Award multiple times and spent time studying and working at Janssen's headquarters in Belgium.

Ding Yuli hold a bachlor's degree from China Phamaceutical University, and a master’s degree in pharmacology Inner Mongolia Medical University.

Dr. Li Amin is currently the Senior Vice President of Chemistry at Jacobio Pharma and is fully responsible for the work related to medicinal chemistry department and Process Development Department.

Dr. Li Amin has more than ten years of experience in the synthesis, target discovery and drug development of anti-cancer drugs. She has led the preclinical development and external communication of multiple Jacobio pipeline programs. Before joining Jacobio, she worked for a well-known CRO company, leading a team of more than 30 people in drug synthesis.

Dr. Li Amin graduated from Peking University School of Medicine with a Ph.D. in chemical biology. She has published an article in JMC (Journal of Medicinal Chemistry) as the first author.

Dr. Wang Haijun is now Senior Vice President at Jacobio, responsible for the design and management of the company’s information systems, as well as bioinformatics and biostatistics.

Dr. Wang Haijun worked abroad for more than 20 years. Prior to joining Jacobio, he was an assistant professor in the Department of Family and Community Medicine at Baylor College of Medicine in the U.S., where he conducted medical information management, data statistical analysis and health service research.

Dr. Wang Haijun holds a doctoral degree in epidemiology and health statistics from the Chinese Center for Disease Control and Prevention (CDC), as well as a master’s degree in chemistry from Lamar University, U.S., and a master’s degree in public health from Beijing Medical University (now Peking University Health Science Center).

Dr. CHEN Yan currently serves as Vice President of CMC at Jacobio Pharma, where he is responsible for process scale-up and optimization for the company’s pipeline programs, as well as CMC-related activities supporting product commercialization.

Prior to joining Jacobio, Dr. Chen was responsible for process development at Porton Pharma Solutions and held positions at BioDuro and GSK. He brings 15 years of experience in CMC, with deep expertise in the CMC development process for small molecules and various new modalities. Dr. Chen has led multiple projects across research and development, manufacturing, and regulatory submissions.

Dr. Chen received his Ph.D. in Applied Chemistry[GU2.1] from Tianjin University.
 

Rick Wu is currently Vice President of Intellectual Property at Jacobio and is responsible for the Company’s intellectual property functions.

Rick has more than ten years of experience in pharmaceutical intellectual property, with extensive expertise in patent portfolio development and global filing strategies covering small molecules, antibodies and antibody-drug conjugates. At Jacobio, he leads the intellectual property team in patent drafting, filing and prosecution for key programs; global portfolio planning and patent family maintenance; freedom-to-operate analyses and competitive intelligence; and intellectual property due diligence and transaction-term support for out-licensing and partnerships. His work provides intellectual property protection for the global development and commercialization of the Company’s pipeline. Prior to joining Jacobio, he worked at a well-established intellectual property services firm, advising pharmaceutical companies in China and overseas.

Rick received his master’s degree in medicinal chemistry from Peking Union Medical College.
 

Isabella Pan is currently Global Head of Business Development at Jacobio, responsible for the Company’s global business development and strategic partnerships, including the in-licensing and out-licensing of innovative medicines, co-development, strategic investments, and mergers and acquisitions. She leads global partner engagement, opportunity assessment, transaction negotiation and execution, as well as alliance management for key partnerships.

Prior to joining Jacobio, Isabella conducted biomedical research at the U.S. National Institutes of Health (NIH) and subsequently worked at several healthcare investment firms and pharmaceutical companies, focusing on business development, investment and strategic partnerships. 

Isabella received her master’s degree in biology from Georgetown University, U.S.
 

Dr. Sun Xin is currently the Vice President of Translational Medicine at Jacobio Pharma.

He is responsible for the translational medical research of Jacobio, exploring and verifying the biomarkers and developing the companion diagnostics for new target drugs, and also participating in project research and target verification. Sun Xin has more than ten years of experience in basic research and new drug R&D in the field of oncology. Before joining Jacobio, he had 7 years of academic experience and served as an associate researcher and master's tutor at Jinan University. He has served as an independent PI (principal investigator) and led a team to engage in translational research in the fields of tumors and other fields, and published more than ten SCI papers.

Sun Xin completed his undergraduate and doctoral degrees at Zhejiang University and completed postdoctoral research at Johns Hopkins University.

YANG Tao is currently Vice President of Human Resources at Jacobio. 

YANG Tao is responsible for promoting the organizational development, construction and implementation of the company. She has more than 20 years of working experience in multinational pharmaceutical companies. She worked in multiple human resources management positions at Novartis, led the successful implementation of multiple organizational changes and talent development programs. For eight years after 2012, she served as head of human resources for Novartis Oncology (China).

YANG Tao graduated from Beijing Normal College (now Capital Normal University) with a bachelor’s degree.

Stella Xue is currently Vice President of Finance at Jacobio. She is responsible for the Company’s day-to-day financial management, corporate administration and government affairs.

Stella began her career at a Big Four accounting firm and worked in its Beijing and U.S. offices, where she was extensively involved in capital markets and financial compliance engagements. She has substantial experience in strategic financial planning, compliance management and cross-border projects.

Stella is a non-practising member of the Chinese Institute of Certified Public Accountants and holds professional qualifications including ACCA, U.S. CPA and CPA, CGA (Canada). She received her bachelor’s degree from Capital University of Economics and Business.